Schizophrenia is a complex psychiatric disorder characterized by perceptual abnormalities including hallucinations and delusions, conceptual disorganization, cognitive impairment, and, frequently, the presence of negative symptoms such as alogia, affective flattening, and avolition.
The lifetime prevalence of the disorder is approximately 1% and it is equally prevalent in men and women. Peak ages of onset for schizophrenia are ages 15-25 for men and 25-35 for women. The morbidity and mortality associated with schizophrenia is much greater than in the general population; patients with schizophrenia have a higher mortality rate from accidents and natural causes than the general population, more than 30% of patients meet criteria for substance abuse disorders, and approximately 10% of patients with schizophrenia die by suicide. 2 Family, twin, and adoption studies have all suggested that schizophrenia has a prominent genetic component 3 with heritability estimates as high as 80%. 4 Moreover, significant linkage results have been reported across several genomic regions, although progress towards the ultimate identification of genetic variants that alter susceptibility to schizophrenia has been limited by the genetic complexity of the disorder. 5 
PHARMACOLOGICAL

TREATMENT OF SCHIZOPHRENIA
Antipsychotic drugs are the mainstay of treatment for schizophrenia. Chlorpromazine was introduced in the 1950s and resulted in significant improvement in the quality of life for many patients with schizophrenia, with a far greater proportion of patients able to live their lives without the restrictions of chronic inpatient hospitalization. Antipsychotic drugs treat many symptoms of the disorder, particularly the florid hallucinations and delusions, and the relapse rates of patients treated with antipsychotic drug treatment are two to four times less than patients treated with placebo. 2 Unfortunately, these medications do not represent a cure for schizophrenia and treated patients often continue to experience psychotic symptoms. Moreover, the traditional antipsychotic agents such as chlorpromazine, haloperidol and thioridazine are associated with acute neuromuscular side effects (extra pyramidal symptoms or EPS) such as acute dystonic reactions and pseudo-parkinsonism, as well as the longer-term side effect of the potentially irreversible movement disorder, tardive dyskinesia (TD). 6 The introduction of clozapine in the late 1980s revolutionized the treatment of schizophrenia. Clozapine was the first antipsychotic agent to produce antipsychotic efficacy without a significant amount of EPS or TD liability. 7 Moreover, clozapine remains the only antipsychotic drug with superior efficacy than traditional antipsychotic drugs for the treatment of poorly responsive or treatment resistant patients. 8 These unique attributes of clozapine led to intensive efforts by the pharmaceutical industry to develop newer 'atypical' antipsychotic agents with diminished neuromuscular side effect liabilities, and resulted in the release of the atypical antipsychotics risperidone, olanzapine, quetiapine and ziprasidone (just approved in 2001). Despite these advances, major clinical problems still exist in the treatment of schizophrenia. In this review, we will consider three important problems with antipsychotic drug treatment: the slow onset of antipsychotic efficacy, the development of antipsychotic-induced side effects, and the predisposition of a subgroup of patients with schizophrenia to rapidly relapse following antipsychotic drug discontinuation; and then discuss the current status of pharmacogenetic approaches to each of these clinical problems.
CLINICAL PROBLEMS IN THE PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIA
The first major drawback of antipsychotic drug treatment with either the traditional or newer antipsychotics is the relatively slow onset of antipsychotic efficacy. Despite the fact that drug-induced side effects may occur shortly after drug administration, antipsychotic efficacy may not be achieved for as long as 4-12 weeks after drug initiation. 9, 10 The time period, therefore, before a clinician can determine that a treatment trial is ineffective and consider an alternative medication, can be lengthy. During this time, treated patients, in addition to suffering disturbing psychotic symptoms, may experience employment loss, social dysfunction, medical morbidity, substance abuse and, in a significant proportion of cases, commit suicide. Clearly, any data on the likelihood that an individual patient might respond (or not respond) to a particular antipsychotic medication would be invaluable in reducing the tremendous morbidity and mortality associated with schizophrenia.
Another concern with antipsychotic drug treatment is the potential for these drugs to cause potentially serious adverse effects. As mentioned above, the traditional antipsychotics are associated with both acute and long-term neuromuscular side effects. In addition, however, the traditional antipsychotics can cause anticholinergic adverse effects, ie tachycardia, blurred vision, dry mouth, constipation, exacerbation of narrow angle glaucoma, urinary hesitancy and retention, as well as hypotension, prolongation of the QT interval, increases in liver function tests and plasma prolactin levels. 6 The newer antipsychotic agents, although less prone to induce the neuromuscular side effects, are also associated with many of these side effects and, in particular, weight gain 11 and increases in ventricular repolarization as measured by the QT interval 12 have been intensively focused on as side effects of the new antipsychotic agents, olanzapine and ziprasidone, respectively. Moreover, approximately 1.5-2% of patients treated with clozapine develop granulocytopenia and 0.05-2% may develop the potentially fatal blood dyscrasia, agranulocytosis. 13, 14 These data have led to the requirement that clozapine-treated patients undergo weekly monitoring of white blood cell counts for the first 6 months of treatment and then biweekly thereafter. This requirement can be inconvenient for patients with schizophrenia, as well as expensive, and therefore has limited the utilization of this particularly effective medication.
Finally, another clinical problem in the treatment of schizophrenia is the difficulty in identifying the patients at the highest risk for relapse following antipsychotic drug discontinuation. 15 Patients with schizophrenia discontinue their medications for multiple reasons. Patients who respond well to treatment may consider themselves 'in remission' and perhaps no longer in need of chronic antipsychotic drug treatment. Poorly responsive patients may believe that the medication is not providing any symptom relief at all and therefore to continue drug treatment is not worth the inconveniences of chronic treatment. Finally, patients who experience significant adverse drug effects may choose not to continue treatment despite experiencing symptom improvement. 16 Following drug discontinuation, there are limited data to suggest which
The Pharmacogenomics Journal patients are at highest risk of suffering an early relapse, with its concomitant morbidity and mortality. A proportion of patients do not experience a relapse for several months without antipsychotic treatment, 17 however, another subgroup of patients can experience significant increases in psychotic symptoms within days of drug discontinuation. 15 Unfortunately, with no methods to identify those patients at highest risk for rapid relapse, and conversely, to identify the patients who might do well without chronic medication for an extended period of time, it is usually recommended that all patients, regardless of clinical status, remain on continuous antipsychotic drug treatment. 17 In fact, attempts to develop intermittent or targeted treatment strategies, have been largely unsuccessful in schizophrenia patients as a group. [18] [19] [20] [21] [22] [23] If a subgroup of patients who might benefit from intermittent treatment could be identified, the proportion of patients committed to chronic antipsychotic treatment could be minimized, and patients at highest risk could be more intensively monitored for compliance with treatment.
Unfortunately, despite several decades of investigation, no clinical or biological predictor of antipsychotic drug response, development of adverse side effects, or predisposition to rapid relapse have been identified. For these reasons, it has been hoped that the introduction of pharmacogenetic approaches to psychiatric research may provide informative data to help guide clinical decision-making in the treatment of this devastating disorder.
PHARMACOGENETIC STUDIES OF ANTIPSYCHOTIC DRUG RESPONSE: CURRENT STATUS
To date, the majority of molecular studies aiming to identify predictors of antipsychotic drug efficacy have focused on clozapine. Pharmacogenetic studies of clozapine's efficacy have primarily focused on the neurotransmitter receptors to which clozapine has the most potent affinity. These include the dopamine D2, D3 and D4 receptors, as well as the serotonergic 5-HT2A, 5HT2C, and 5-HT6 receptors. The data thus far have been somewhat inconsistent with both positive and negative associations at most of the candidate receptors (Table  1) . In general, it appears that the associations between the 5-HT2A receptor gene and clozapine response are the strongest. Several studies have yielded weakly positive results and a meta analysis of all of the published studies of the two 5-HT2A polymorphisms, T102C and His452Tyr, and clozapine response, indicated that this gene has a significant, albeit small, effect on the variation in clozapine response. 24 It should be noted that the a priori probability that the 5-HT2A T102C polymorphism influences function is low, as T102C is a silent substitution, however T102C appears to be in linkage identity with a promoter region polymorphism that may influence 5-HT2A receptor gene transcription.
Finally, Arranz and colleagues 25 have recently conducted an analysis of 19 polymorphisms within clozapinetargeted receptor subtypes and identified a group of six polymorphisms that provided 76.7% success in predicting clozapine response. Although the authors suggested that this result would lead to a simple predictive test for clozapine response, these data have thus far not been replicated. 26 There are multiple potential explanations for the lack of consensus in these initial clozapine pharmacogenetic studies. From a clinical perspective, the patient populations enrolled in the initial clozapine clinical trials were usually chronic schizophrenia patients with a history of poor response to typical neuroleptics. [27] [28] [29] Therefore, patients who responded well to antipsychotic drugs were screened out of these studies-decreasing the potential variance in clozapine response. As phenotypic variation influences the power of genetic association studies, this could result in decreased power to detect the effects of genetic variation on drug response. 30 A second clinical concern in these initial studies is that clozapine-treated patients had been exposed to multiple previous traditional antipsychotic treatment trials. As antipsychotic the inter-individual variation in patient's prior drug exposure may introduce additional environmental variation into an already complex phenotype. Finally, many of the initial clozapine pharmacogenetic studies utilized non-standardized clozapine dosages and durations of treatmenttherefore introducing further variation into these analyses. From a genetics perspective, the issue of population stratification between clozapine responders and non-responders has also been difficult to definitively address, 30 as well as the problem of the comparability of data derived from studies conducted in different populations. 33 Moreover, the negative studies of clozapine response generally contained smaller sample sizes, and therefore had limited power to detect alleles of small to modest effect. Finally, the utilization of polymorphisms for which there is no evidence to support a functional role (at least at the cellular level) increases the potential for false positive and negative results secondary to chance.
Because of these concerns, pharmacogenetic studies in schizophrenia may benefit from utilization of different designs with enhanced power to detect small to modest gene effects on www.nature.com/tpj drug response. First, use of clinical trials populations that have not been previously treated may provide samples in which treatmentresponders have not been screened out, and in which variation in prior drug exposure will not influence results. Second, as case-control studies are more powerful than family-based association designs, newly developed genomic control techniques 34 may provide the means to ascertain large sample sizes in which population stratification can be empirically determined and accounted for. Finally studies that focus on the use of polymorphisms with demonstrated effects on cellular function may provide greater a priori probability of detecting meaningful associations. For polymorphisms for which functional data are unavailable, utilization of non-synonymous SNPs or variants in regulatory regions may provide greater power.
Another application of pharmacogenetic techniques in schizophrenia has been in the domain of adverse effects. In particular, the traditional antipsychotic agents have been associated with the long term movement disorder tardive dyskinesia. As the majority of data on the pathophysiology of TD implicate the dopaminergic system, several studies have investigated the relationship between dopamine receptor gene polymorphisms and TD, as measured by standardized rating scales such as the Abnormal Involuntary Movement Scale (AIMS). Although sample sizes have been relatively small, a dopamine D3 receptor polymorphism Ser9Gly that may alter dopamine binding affinity 35 has been reported to alter susceptibility to TD in several studies. Moreover, there have been a number of reports suggesting that polymorphisms within the cytochrome p450 enzyme CYP2D6, a major enzyme in the oxidative metabolism of many antipsychotic drugs, are associated with development of TD, [36] [37] [38] as well as reports indicating that an intronic polymorphism in the CYP1A2 gene may contribute to TD risk. [39] [40] Clozapine-induced agranulocytosis is another side effect that has been studied in a number of populations. The high incidence of recurrence of agranulocytosis following clozapine rechallenge has suggested that genetic factors play a role in this adverse effect. To date, the focus of investigation has been the major histocompatibility complex (MHC) and human leukocyte antigen (HLA) variants, with specific HLA haplotypes being associated with agranulocytosis in Ashkenazi Jewish and in non-Jewish populations. 41, 42 Moreover, the HLA -A1 allele has been associated with low risk of agranulocytosis, and clinical response to clozapine. 43 These studies are limited by the infrequency of clozapine-induced agranulocytosis and resultant small sample sizes for examination. Nevertheless, with the preponderance of data suggesting a link between HLA alleles and this important side effect, further work in this area could have significant clinical implications.
Finally, the newer antipsychotics are also associated with side effects-such as weight gain and prolongation of the QT interval-that may have significant clinical impact. As there are several candidate genes for these phenotypes (based upon the biology of obesity and inherited syndromes of QT prolongation), pharmacogenetic studies are now under way to assess their relationship in schizophrenia popu-lations in clinical trials of the new antipsychotics.
The hypothesis that schizophrenia patients at highest risk for rapid relapse can be identified through molecular genetic approaches, has not been extensively tested because of the difficulty in ascertaining appropriate patient populations. In a preliminary study, we examined 41 schizophrenia patients who had undergone traditional antipsychotic drug discontinuation as part of a placebo-controlled trial of clozapine. 44 In this study, patients were genotyped at the bi-allelic (long vs short) 5-HTTLPR polymorphism in the promoter region of the serotonin transporter gene. 5-HTTLPR is of interest in psychiatric phenotypes because it has significant effects on 5-HTT gene transcription and synaptic serotonin levels, 45 is associated with both normal behavioral traits 45 and psychiatric disorders, 46 and is the primary site of action of the antidepressant agents, fluoxetine, sertraline and paroxetine. 47 In this study, 56% (9/16) of patients who were homozygous for the long allele (ll) of 5-HTTLPR reported significant increases in psychotic symptoms within 4 weeks of drug discontinuation, in comparison to 14% (3/21) of the heterozygotes and 25% (1/4) of patients with the ss genotype. Moreover, the symptom increases were most marked in the domain of positive symptoms (as assessed by the Brief Psychiatric Rating Scale or BPRS), which include hallucinations, thought disorder and delusions (Figure 1 ). These preliminary data require independent replication but suggest that it may be feasible to utilize molecular genetic techniques to provide individualized risk-benefit information to schizophrenia patients who are considering antipsychotic drug discontinuation.
CONCLUSIONS
Pharmacogenetic techniques may provide a powerful means to dissect the heterogeneity of antipsychotic drug response. To date, there have been intriguing preliminary data but, as yet, no consistently confirmed molecular variant associated with either clinical response, adverse effects or rapid
The Pharmacogenomics Journal Figure 1 The association between the 5-HTTLPR genotype and changes in BPRS thought disturbance ratings following antipsychotic drug discontinuation in 41 patients with schizophrenia or schizoaffective disorder. The BPRS thought disturbance factor includes ratings of hallucination, delusions, and thought disorganization.
relapse following drug discontinuation. With the advent of large scale clinical trials of antipsychotic drugs that include DNA collection, the sequencing of the human genome and concomitant SNP identification efforts, and the development of genomic control techniques to account for population stratification, 34 the next generation of pharmacogenetic studies will be increasingly more powerful, and should provide informative data on the molecular underpinnings of antipsychotic drug response. 
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